Skip to main content
Terug
JNDOF logo

JINS HOLDINGS Inc.

Datakwaliteit: 100%
Overbought
JNDOF
OTC Healthcare Medical - Instruments & Supplies
€ 22,75
€ 0,00 (0,00%)
Marktkapitalisatie: 531,02M
Dagbereik
€ 22,75 € 22,75
52-Weeksbereik
€ 22,75 € 23,00
Volume
300
50D / 200D Gem.
€ 22,75 / € 22,75
Vorige Slotkoers
€ 22,75

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 29,1 3,7
Net Margin % 8,6 3,8
Rev Growth 5Y % 11,1 10,0
D/E 0,2 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 544,32
€ 526,96 – € 566,36
 130 B 1
FY2028 € 489,04
€ 473,44 – € 508,84
 130 B 1
FY2027 € 417,59
€ 404,27 – € 434,50
 120 B 1

Belangrijkste Punten

Revenue grew 11,06% annually over 5 years — strong growth
Earnings grew 78,33% over the past year
ROE of 29,06% indicates high profitability
Debt/Equity of 0,18 — conservative balance sheet
Generating 8,53B in free cash flow
P/E of 0,06 — trading at a low valuation

Groei

Revenue Growth (5Y)
11,06%
Revenue (1Y)17,13%
Earnings (1Y)78,33%
FCF Growth (3Y)86,18%

Kwaliteit

Return on Equity
29,06%
ROIC24,21%
Net Margin8,57%
Op. Margin12,44%

Veiligheid

Debt / Equity
0,18
Current Ratio1,32
Interest Coverage78,02

Waardering

P/E Ratio
0,06
P/B Ratio0,02
EV/EBITDA-0,47
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 17,13% Revenue Growth (3Y) 15,19%
Earnings Growth (1Y) 78,33% Earnings Growth (3Y) 117,43%
Revenue Growth (5Y) 11,06% Earnings Growth (5Y) 26,12%
Profitability
Revenue (TTM) 97,22B Net Income (TTM) 8,33B
ROE 29,06% ROA 14,40%
Gross Margin 77,99% Operating Margin 12,44%
Net Margin 8,57% Free Cash Flow (TTM) 8,53B
ROIC 24,21% FCF Growth (3Y) 86,18%
Safety
Debt / Equity 0,18 Current Ratio 1,32
Interest Coverage 78,02 Dividend Yield 0,03%
Valuation
P/E Ratio 0,06 P/B Ratio 0,02
P/S Ratio 0,01 PEG Ratio 0,12
EV/EBITDA -0,47 Dividend Yield 0,03%
Market Cap 531,02M Enterprise Value -5,72B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 97,22B 83,00B 73,26B 66,90B 63,90B
Net Income 8,33B 4,67B 1,76B 750,00M 3,29B
EPS (Diluted) 356,89 191,22 69,42 27,37 127,35
Gross Profit 75,81B 64,45B 56,26B 52,13B 50,41B
Operating Income 12,09B 7,84B 4,85B 3,32B 5,05B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 57,86B 54,04B 44,86B 54,72B 53,00B
Total Liabilities 26,12B 28,45B 23,08B 34,31B 32,78B
Shareholders' Equity 31,74B 25,59B 21,78B 20,41B 20,22B
Total Debt 5,73B 12,37B 12,51B 22,82B 23,35B
Cash & Equivalents 11,98B 18,67B 12,20B 21,43B 23,21B
Current Assets 28,65B 32,25B 23,76B 33,17B 33,21B
Current Liabilities 21,72B 25,66B 11,27B 22,70B 10,50B

Strategiescores

This stock passed the criteria for 8 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#328 of 1052
54
Custom Deep Value Investing (Seth Klarman)
#164 of 827
59
Growth Price/Sales Ratio Focus (Ken Fisher)
#446 of 618
21
Custom Contrarian Investing (David Dreman)
#448 of 670
18
Value Defensive Investing (Benjamin Graham)
#388 of 709
26
Value Value Investing (Warren Buffett)
#110 of 203
41
Custom Balanced Risk
#73 of 151
47
Custom Lower Risk
#53 of 140
49

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026